What Logenex Pharm Gmbh does

LOGENEX Pharm GmbH is a privately held German pharmaceutical company headquartered at Martinistrasse 13, Hamburg, operating under the legal form of a Gesellschaft mit beschränkter Haftung (GmbH). The company specializes in the development and distribution of high-quality generic and niche pharmaceuticals targeted at specific therapeutic areas, with a current product portfolio of five core SKUs: Anatrofer® 1000 mg (sodium hydrogen carbonate gastro-resistant tablets for metabolic acidosis in chronic kidney disease), Bortezomib 3.5 mg injection, Pemetrexed 500 mg infusion, Testosteron 1000 mg/4 mg injection, and Zoledronsäure 4 mg/5 ml infusion concentrate. All products are manufactured, tested, and released in certified production facilities within the European Union in strict accordance with Good Manufacturing Practice (GMP) guidelines; the company itself holds a wholesale distribution authorization under § 52a (1) of the German Medicines Act (AMG), issued by the Hamburg authority responsible for medicinal products and consumer protection.

The company operates an asset-light, B2B go-to-market model. Products are registered and marketed through a network of distribution partners across Europe, North Africa, the Middle East, Southeast Asia, and Latin America. Three partners anchor the distribution architecture: CNX Therapeutics handles international specialty and hospital channels across 35+ countries, CareCept Medical serves as the sales and distribution partner in Germany with a focus on oncology, and PharmIdea SIA functions as a strategic co-development partner for sterile formulation manufacturing in gynecology and oncology. End customers are healthcare professionals, hospital systems, and patients requiring treatment in nephrology (specifically CKD-related metabolic acidosis) and oncology. Revenue is generated through product sales via this partner channel structure; the company lists "one-time license" revenue streams and pricing is not publicly disclosed. The organization is led by General Manager (Geschäftsführer) Frank Materne, with no disclosed external ownership, venture backing, or public listing.

The company's competitive positioning rests on EU GMP manufacturing provenance, a niche therapeutic focus in CKD metabolic acidosis and oncology, and supply reliability for healthcare system partners. The headquarters is registered with the District Court of Hamburg under HRB 110224.

Name

Logenex Pharm Gmbh

Legal name

LOGENEX Pharm GmbH

Website

https://logenex-pharm.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

LOGENEX Pharm GmbH is an independent German pharmaceutical company based in Hamburg that develops and distributes EU-manufactured generic and niche pharmaceuticals, primarily for nephrology (CKD metabolic acidosis) and oncology, via a partner distribution network across Europe, North Africa, the Middle East, Southeast Asia, and Latin America.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Full-Line Pharmaceutical Wholesalers (HLAIAJAA), Nephrology & Urology Pharmaceuticals (HLAIAAAM)

Keywords

• Generic pharmaceuticals
• Pharmaceutical wholesale distribution
• Nephrology therapeutics
• Oncology generics
• Hospital specialty medicines

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Generic Pharmaceuticals: Development and distribution of high-quality generic pharmaceuticals and niche products for specific therapeutic areas including chronic kidney disease and oncology.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

LOGENEX Pharm GmbH is an independent German pharmaceutical company that develops and distributes high-quality generic and niche pharmaceutical products for specific therapeutic areas, primarily chronic kidney disease (metabolic acidosis) and oncology. Products are sourced exclusively from qualified manufacturers within the European Union and manufactured, tested, and released under strict Good Manufacturing Practice (GMP) guidelines. Marketing and distribution are executed through a network of wholesale and channel partners across Europe, North Africa, the Middle East, Southeast Asia, and Latin America.

Product overview

LOGENEX Pharm GmbH is an independent German pharmaceutical company specializing in the development and distribution of high-quality generics and niche products. The product portfolio includes Anatrofer® 1000 mg (gastro-resistant tablets for metabolic acidosis treatment in chronic kidney disease patients), Bortezomib 3.5 mg (injection solution), Pemetrexed 500 mg (infusion solution), Testosteron 1000 mg/4 mg (injection solution), and Zoledronsäure 4 mg/5 ml (infusion solution concentrate). All products are manufactured in certified production facilities within the European Union following Good Manufacturing Practice (GMP) guidelines.

Differentiator

Problem solved

Functional benefit

Products and services

• Anatrofer 1000 mg (Sodium hydrogen carbonate)

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• PharmIdea SIAcoreStrategic or Co-development PartnerPharmIdea SIA focuses on research and manufacturing of medications for hospitals, specializing in gynecology and oncology. They have core competencies in research, development and production of sterile formulations. LOGENEX partners with PharmIdea for product development.
• CareCept MedicalcoreChannel Partner/ Reseller/ DistributorCareCept medical specializes in pharmaceutical distribution in Germany with particular focus on oncology. They serve as the sales and distribution partner for LOGENEX products in the German market.
• CNX TherapeuticscoreChannel Partner/ Reseller/ DistributorCNX Therapeutics distributes a portfolio of specialty brands and hospital products in Europe and through partners in over 35 countries worldwide. They are a key distribution partner for LOGENEX's international expansion.

Scale indicators1 record

Recent moves7 records

Expansion highlights4 records

Direct peers

• STADA Arzneimittel AG: German-headquartered generics and specialty pharmaceutical company with broad European distribution and a hospital/oncology portfolio — the closest direct comparable to LOGENEX in scale, geography, and therapeutic mix.
• Tillomed Pharma GmbH: German specialty generics company focused on hospital injectables and oncology, with cross-border distribution — directly comparable therapeutic and channel mix to LOGENEX.
• CNX Therapeutics: Specialty and hospital pharmaceutical distributor operating across Europe and 35+ countries — both a key channel partner and an operational peer given its overlapping oncology and hospital product portfolio.
• Medice Arzneimittel Pütter GmbH: Independent German pharmaceutical company with branded generics and specialty products, including nephrology adjacencies — comparable in operating model and German-market positioning.
• CareCept Medical: German pharmaceutical distributor with an oncology focus; LOGENEX's domestic sales partner and a structural peer in niche hospital oncology distribution in Germany.
• HORMOSAN Pharma GmbH: German specialty pharma focused on niche and rare-disease generics, including nephrology — comparable as a similarly sized, niche-focused German generics specialist.

Broad incumbents

• ratiopharm (Teva): Well-established German generics brand under Teva with broad OTC/Rx portfolio, large-scale distribution and significant presence in the same hospital tender markets LOGENEX targets.
• Hexal AG (Sandoz): Major German generics subsidiary of Sandoz with extensive hospital and CKD-relevant product lines; competes head-to-head with LOGENEX in the German generics and nephrology-adjacent space.
• Aurobindo Pharma Deutschland: Subsidiary of a major Indian generics group active in European hospital injectables, including oncology — competes on price and scale in the same tenders LOGENEX addresses.

Emerging players

• PharmIdea SIA: EU-based sterile formulation CDMO specializing in oncology and gynecology injectables; LOGENEX's co-development partner but also a peer in sterile injectable capabilities for hospital channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/logenex-pharm-gmbh

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Logenex Pharm Gmbh